“Mental health is poised to become the world’s leading disease burden. ATAI is advancing an evidence-based approach across a portfolio of medicines, each aimed at the various mental health challenges we face across the world today.”
Thiel Capital’s Jason Camm Discusses Joining Psychedelics Company ATAI Following $24 Million Raise
